<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02463097</url>
  </required_header>
  <id_info>
    <org_study_id>CEP 294</org_study_id>
    <nct_id>NCT02463097</nct_id>
  </id_info>
  <brief_title>Hybrid Closed Loop Pivotal Trial in Type 1 Diabetes</brief_title>
  <official_title>Safety Evaluation of the Hybrid Closed Loop (HCL) System in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a single-arm, multi-center, Home and Hotel Clinical Investigation in subjects&#xD;
      with type 1 diabetes on insulin pump therapy. The purpose of this study is to demonstrate&#xD;
      that the closed loop algorithm that is built into the 670G insulin pump is safe as part of&#xD;
      the overall system.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will proceed as follows:&#xD;
&#xD;
      Run-in Period:&#xD;
&#xD;
      A total of up to 150 subjects (age 14 - 75) will be enrolled at up to 10 investigational&#xD;
      centers (9 in the US, 1 in the Europe, Middle East and Africa (EMEA) region) in order to&#xD;
      reach 100 subjects who will complete the HCL study. The 2-week run-in period will be used to&#xD;
      allow subjects to become familiar with new study devices. During the two week run-in period&#xD;
      subjects will be using the Study Pump (670G) with the Sensor Augmented Pump function only&#xD;
      activated (i.e. SmartGuard OFF and HCL OFF).&#xD;
&#xD;
      Study Period - At Home:&#xD;
&#xD;
      Following the two week run-in period using the Study Pump (670G), all subjects will&#xD;
      participate in a 3-month study period.&#xD;
&#xD;
      Subjects will be required to have a companion with them during the night for the duration of&#xD;
      the study period. Companions will need to be under the same roof, but not necessarily in the&#xD;
      same bedroom. During the Hotel stay where subjects are monitored closely, the presence of a&#xD;
      companion is not necessary.&#xD;
&#xD;
      Study Period - Hotel Study Subjects will participate in a Hotel study (6 days, 5 nights),&#xD;
      with the remainder of the study period to be spent at home.&#xD;
&#xD;
      All subjects will undergo daytime and nighttime Frequent Sample Testing (FST) for&#xD;
      approximately 24 hours during the Hotel study with YSI or i-STAT® used as a reference value.&#xD;
&#xD;
      With respect to meals, subjects will be allowed to eat as they normally do.&#xD;
&#xD;
      Continued Access Program Subjects will be given the opportunity to extend use of their study&#xD;
      devices for a period of 3 years. If subjects choose to participate in the continuation&#xD;
      period, they will retain the study devices at the end of study period visit or receive them&#xD;
      back in the event they have been returned to study staff already. During the continuation&#xD;
      period, subjects will come in for office visits every 3 months. At each of the quarterly&#xD;
      visits, subjects will be asked about the occurrence of adverse events and device complaints.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in A1C</measure>
    <time_frame>Baseline and 3 months</time_frame>
    <description>There is no statistically powered primary endpoint in this study. However, there will be a descriptive analysis of change in A1C.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Severe Hypoglycemia Events</measure>
    <time_frame>3 months</time_frame>
    <description>There is no statistically powered secondary endpoint in this study. However, there will be a descriptive analysis of the number of Severe Hypoglycemia events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Diabetic Ketoacidosis (DKA) Events</measure>
    <time_frame>3 months</time_frame>
    <description>There is no statistically powered secondary endpoint in this study. However, there will be a descriptive analysis on number of Diabetic Ketoacidosis (DKA) Event.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">124</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Study Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insulin Pump</intervention_name>
    <description>Closed Loop Algorithm</description>
    <arm_group_label>Study Arm</arm_group_label>
    <other_name>MMT-670G</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Is age 14 - 75 years at time of screening&#xD;
&#xD;
          2. Has a clinical diagnosis of type 1 diabetes for 2 years or more as determined via&#xD;
             medical record or source documentation by an individual qualified to make a medical&#xD;
             diagnosis&#xD;
&#xD;
          3. Is willing to participate in a hotel study for the specified duration of hotel stay.&#xD;
&#xD;
          4. Must have companion who will sleep in the same dwelling place every night during the&#xD;
             study period and should also be able to call the subject daily in the event the&#xD;
             subject is traveling.&#xD;
&#xD;
          5. Is willing to perform ≥ 4 finger stick blood glucose measurements daily&#xD;
&#xD;
          6. Is willing to perform required sensor calibrations&#xD;
&#xD;
          7. Is willing to wear the system continuously throughout the study&#xD;
&#xD;
          8. Has a Glycosylated hemoglobin (A1C) value less than 10.0% (as processed by Central&#xD;
             Lab) at time of screening visit&#xD;
&#xD;
          9. Has TSH in the normal range OR if the TSH is out of normal reference range the Free T3&#xD;
             is below or within the lab's reference range and Free T4 is within the normal&#xD;
             reference range.&#xD;
&#xD;
         10. Pump therapy for greater than 6 months prior to screening (with or without CGM&#xD;
             experience)&#xD;
&#xD;
         11. Is willing to upload data from the study pump, must have Internet access and a&#xD;
             computer system that meets the requirements for uploading the study pump&#xD;
&#xD;
         12. If subject has celiac disease, it has been adequately treated as determined by the&#xD;
             investigator&#xD;
&#xD;
         13. Is willing to take one of the following insulins and can financially support the use&#xD;
             of either of the 2 insulin preparations throughout the course of the study (i.e.&#xD;
             co-payments for insulin with insurance or able to pay full amount)&#xD;
&#xD;
               -  Humalog® (insulin lispro injection)&#xD;
&#xD;
               -  NovoLog® (insulin aspart)&#xD;
&#xD;
         14. With history of cardiovascular event 1 year or more from the time of screening must&#xD;
             have an EKG within 6 months prior to screening or during screening. If subject has an&#xD;
             abnormal EKG, participation is allowed if there is clearance from a cardiologist&#xD;
&#xD;
         15. With 3 or more cardiovascular risk factors listed below must have an EKG within 6&#xD;
             months prior to screening or during screening. If subject has an abnormal EKG,&#xD;
             participation is allowed if there is clearance from a cardiologist&#xD;
&#xD;
             Cardiovascular risk factors include:&#xD;
&#xD;
               -  Age &gt;35 years&#xD;
&#xD;
               -  Type 1 diabetes of &gt;15 years' duration&#xD;
&#xD;
               -  Presence of any additional risk factor for coronary artery disease&#xD;
&#xD;
               -  Presence of microvascular disease (proliferative retinopathy or nephropathy,&#xD;
                  including microalbuminuria)&#xD;
&#xD;
               -  Presence of peripheral vascular disease&#xD;
&#xD;
               -  Presence of autonomic neuropathy&#xD;
&#xD;
         16. With history of cardiovascular event 1 year or more from the time of screening must&#xD;
             have a stress test within 6 months prior to screening or during run in period. If&#xD;
             subject fails stress test, participation is allowed if there is clearance from a&#xD;
             cardiologist&#xD;
&#xD;
         17. Must be able to speak and be literate in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the&#xD;
             following during the 6 months prior to screening:&#xD;
&#xD;
               -  Medical assistance (i.e. Paramedics, Emergency Room ( ER) or Hospitalization)&#xD;
&#xD;
               -  Coma&#xD;
&#xD;
               -  Seizures&#xD;
&#xD;
          2. Is unable to tolerate tape adhesive in the area of sensor placement&#xD;
&#xD;
          3. Has any unresolved adverse skin condition in the area of sensor placement (e.g.,&#xD;
             psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection)&#xD;
&#xD;
          4. Females who are sexually active and able to conceive will be excluded if they are not&#xD;
             using an effective method of contraception and do not agree to continue using an&#xD;
             effective method of contraception for the duration of the study as determined by&#xD;
             investigator.&#xD;
&#xD;
          5. Has had any of the following cardiovascular events within 1 year of screening:&#xD;
             myocardial infarction, unstable angina, coronary artery bypass surgery, coronary&#xD;
             artery stenting, transient ischemic attack, cerebrovascular accident, angina,&#xD;
             congestive heart failure, ventricular rhythm disturbances or thromboembolic disease&#xD;
&#xD;
          6. Is being treated for hyperthyroidism at time of screening&#xD;
&#xD;
          7. Has diagnosis of adrenal insufficiency&#xD;
&#xD;
          8. Has had DKA in the 6 months prior to screening visit.&#xD;
&#xD;
          9. Has taken any oral, injectable, or intravenous (IV) steroids within 8 weeks from time&#xD;
             of screening visit, or plans to take any oral, injectable, or IV steroids during the&#xD;
             course of the study&#xD;
&#xD;
         10. Actively participating in an investigational study (drug or device) wherein he/she has&#xD;
             received treatment from an investigational study drug or investigational study device&#xD;
             in the last 2 weeks&#xD;
&#xD;
         11. Has been hospitalized or has visited the ER in the 6 months prior to screening&#xD;
             resulting in a primary diagnosis of uncontrolled diabetes&#xD;
&#xD;
         12. Currently abusing illicit drugs&#xD;
&#xD;
         13. Currently abusing marijuana.&#xD;
&#xD;
         14. Currently abusing prescription drugs&#xD;
&#xD;
         15. Currently abusing alcohol&#xD;
&#xD;
         16. Using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1&#xD;
             agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of&#xD;
             screening&#xD;
&#xD;
         17. Has a history of visual impairment which would not allow subject to participate in the&#xD;
             study and perform all study procedures safely, as determined by the investigator&#xD;
&#xD;
         18. Has elective surgery planned that requires general anesthesia during the course of the&#xD;
             study&#xD;
&#xD;
         19. Has a sickle cell disease, hemoglobinopathy; or has received red blood cell&#xD;
             transfusion or erythropoietin within 3 months prior to time of screening&#xD;
&#xD;
         20. Plans to receive red blood cell transfusion or erythropoietin over the course of study&#xD;
             participation&#xD;
&#xD;
         21. Diagnosed with current eating disorder such as anorexia or bulimia&#xD;
&#xD;
         22. Diagnosed with chronic kidney disease that results in chronic anemia&#xD;
&#xD;
         23. Hematocrit that is below the normal reference range of lab used.&#xD;
&#xD;
         24. On dialysis&#xD;
&#xD;
         25. Serum creatinine of &gt;2 mg/dL.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes (Adult)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes (Pediatric)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicollet Clinic-International Diabetes Center - Adult and Pediatric</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainer Clinical Research Center</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Endocrinology, Sheba Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 28, 2015</study_first_submitted>
  <study_first_submitted_qc>June 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2015</study_first_posted>
  <results_first_submitted>March 7, 2017</results_first_submitted>
  <results_first_submitted_qc>March 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 18, 2017</results_first_posted>
  <last_update_submitted>April 11, 2019</last_update_submitted>
  <last_update_submitted_qc>April 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Arm</title>
          <description>All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm&#xD;
Insulin Pump: Closed Loop Algorithm&#xD;
i-STAT blood testing: Intravenous i-STAT blood testing is used for reference validation&#xD;
Blood Glucose Meter testing: Frequent finger stick blood glucose testing using a Blood Glucose meter is required</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="123"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm.</population>
      <group_list>
        <group group_id="B1">
          <title>Study Arm</title>
          <description>All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm&#xD;
Insulin Pump: Closed Loop Algorithm&#xD;
i-STAT blood testing: Intravenous i-STAT blood testing is used for reference validation&#xD;
Blood Glucose Meter testing: Frequent finger stick blood glucose testing using a Blood Glucose meter is required</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.8" spread="16.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in A1C</title>
        <description>There is no statistically powered primary endpoint in this study. However, there will be a descriptive analysis of change in A1C.</description>
        <time_frame>Baseline and 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Arm</title>
            <description>All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm&#xD;
Insulin Pump: Closed Loop Algorithm&#xD;
i-STAT blood testing: Intravenous i-STAT blood testing is used for reference validation&#xD;
Blood Glucose Meter testing: Frequent finger stick blood glucose testing using a Blood Glucose meter is required</description>
          </group>
        </group_list>
        <measure>
          <title>Change in A1C</title>
          <description>There is no statistically powered primary endpoint in this study. However, there will be a descriptive analysis of change in A1C.</description>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Severe Hypoglycemia Events</title>
        <description>There is no statistically powered secondary endpoint in this study. However, there will be a descriptive analysis of the number of Severe Hypoglycemia events.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Arm</title>
            <description>All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm&#xD;
Insulin Pump: Closed Loop Algorithm&#xD;
i-STAT blood testing: Intravenous i-STAT blood testing is used for reference validation&#xD;
Blood Glucose Meter testing: Frequent finger stick blood glucose testing using a Blood Glucose meter is required</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Severe Hypoglycemia Events</title>
          <description>There is no statistically powered secondary endpoint in this study. However, there will be a descriptive analysis of the number of Severe Hypoglycemia events.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Diabetic Ketoacidosis (DKA) Events</title>
        <description>There is no statistically powered secondary endpoint in this study. However, there will be a descriptive analysis on number of Diabetic Ketoacidosis (DKA) Event.</description>
        <time_frame>3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Arm</title>
            <description>All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm&#xD;
Insulin Pump: Closed Loop Algorithm&#xD;
i-STAT blood testing: Intravenous i-STAT blood testing is used for reference validation&#xD;
Blood Glucose Meter testing: Frequent finger stick blood glucose testing using a Blood Glucose meter is required</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Diabetic Ketoacidosis (DKA) Events</title>
          <description>There is no statistically powered secondary endpoint in this study. However, there will be a descriptive analysis on number of Diabetic Ketoacidosis (DKA) Event.</description>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 Month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Arm</title>
          <description>All subjects wearing the MMT-670G insulin pump, using it with the closed loop algorithm&#xD;
Insulin Pump: Closed Loop Algorithm&#xD;
i-STAT blood testing: Intravenous i-STAT blood testing is used for reference validation&#xD;
Blood Glucose Meter testing: Frequent finger stick blood glucose testing using a Blood Glucose meter is required</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Bacterial arthritis of right wrist</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-difficile diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA15.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Benign paroxysmal positional vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Abdominal pain for few days</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gastro pain (upset stomach), nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Heart burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infiltration. bruising.</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Irritation on sensor site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Iv site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Type 4 skin hypersensitivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute frontal sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Bacterial conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Cold</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Cold-upper respiratory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Common cold</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Gastrointestinal virus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Head cold</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Intestinal virus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Left leg cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Mononucleosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Periodontal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Sinus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Stomach flu</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Uti</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Viral illness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abrasion to left great toe</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Ankle sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Bicycle injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Cracked ulna</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Severe hyperglycemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Intermittent headaches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Deviated septum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Upper respiratory congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Thoub</name_or_title>
      <organization>Medtronic Minimed</organization>
      <phone>8185763142</phone>
      <email>thomas.troub@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

